Special Issue

Artificial Intelligence for Drug Discovery and Developments

Message from the Guest Editors

Intelligent computing technology has demonstrated its capabilities in almost all fields of science and engineering. The use of intelligent computing techniques to explore mechanisms in drug discovery and to draw meaningful conclusions is playing an increasingly important role in biology and medicine. Intelligent computational methods have shown their superior potential in drug target identification, drug repurposing, and drug molecular recombination, helping to solve problems such as drug design and disease diagnosis. Therefore, the use of intelligent computing techniques to analyze and interpret these data is becoming a hot topic in computational biology research. Therefore, we are organizing a Special Issue of *Biomedicines* entitled *Artificial Intelligence for Drug Discovery and Development* and are soliciting technical papers on drug discovery, proteomics, non-coding RNA association recognition, and bioinformatics through intelligent computing technologies. The purpose of this Special Issue is to present the latest research advances in the field of bioinformatics, and we welcome your contributions!

Guest Editors

Prof. Dr. Lei Wang

1. Big Data and Intelligent Computing Research Center, Guangxi Academy of Sciences, Nanning 530007, China
2. Xinjiang Technical Institutes of Physics and Chemistry, Chinese Academy of Sciences, Urumqi 830011, China

Prof. Dr. Zhu-Hong You

School of Computer Science, Northwestern Polytechnical University, Xi'an 710129, China

Deadline for manuscript submissions

closed (31 October 2023)

Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/
biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).